Episode 148: Today, Ann is joined by Ben Zeskind, PhD, Co-Founder and CEO of Immuneering. They break down the science behind cancer treatment and how the company’s Deep Cyclic Inhibitors are taking a different approach to pancreatic cancer by targeting not just tumors, but why treatments fail over time. They also discuss how the technology aims to improve survival rates while maintaining quality of life. Finally, Ben explains why biotech stocks don’t always reflect clinical progress, Immuneering’s late-stage trials, and what’s next for the company.
www.brewmarkets.com
Subscribe to the Brew Markets newsletter: https://www.morningbrew.com/brew-mark...
Follow Brew Markets on social:
Instagram: instagram.com/brewmarkets
TikTok: tiktok.com/@brewmarkets
X: x.com/brewmarkets
Follow Ann Berry on social:
Instagram: instagram.com/annberry_nyc
X: x.com/AnnBerry_NYC
Listen to Brew Markets Here: swap.fm/l/9Qk4z73Z2nEwFiCB4qee
Watch Brew Markets Here: https://www.youtube.com/@BrewMarkets
Disclosure for podcast description: Paid endorsement. Brokerage services provided by Open to the Public Investing Inc, member FINRA & SIPC. Investing involves risk. Not investment advice. Generated Assets is an interactive analysis tool by Public Advisors. Output is for informational purposes only and is not an investment recommendation or advice. See disclosures at public.com/disclosures/ga. Past performance does not guarantee future results, and investment values may rise or fall. See terms of match program at https://public.com/disclosures/matchprogram. Matched funds must remain in your account for at least 5 years. Match rate and other terms are subject to change at any time.
The content shared on this podcast is for informational and entertainment purposes only and should not be considered financial, legal, or investment advice. Brew Markets, Morning Brew and their hosts are not licensed financial advisors. Listeners should conduct their own research and consult with qualified professionals before making any financial decisions or investments. The views expressed are those of the hosts and guests and do not necessarily reflect the views of Morning Brew or its affiliates. This podcast may include paid endorsements or sponsorships
Learn more about your ad choices. Visit megaphone.fm/adchoices
